おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Tempest Therapeutics
company
About
Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor pathways.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $70M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2011
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response.Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$85M
Tempest Therapeutics has raised a total of
$85M
in funding over 2 rounds. Their latest funding was raised on
Apr 27, 2022 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 27, 2022 | Post-IPO Equity | $15M | 1 | — | — | Detail |
| Mar 28, 2018 | Series B | $70M | 2 |
Versant Ventures
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
Tempest Therapeutics is funded by 2 investors.
Versant Ventures
and Lilly Asia Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Versant Ventures
|
— | Post-IPO Equity |
Lilly Asia Ventures
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
